This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Lloyd A, Holman A, Evers T.A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial. Current Medical Research and Opinion 24: 1279-1294, No. 5, 2008
Rights and permissions
About this article
Cite this article
Moxifloxacin cost saving for community-acquired pneumonia. Pharmacoecon. Outcomes News 554, 4 (2008). https://doi.org/10.2165/00151234-200805540-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805540-00006